Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2001

View Archived Issues

Delta Pharmaceuticals reports name change

Pharmacological profile of Ono-6818, an orally active HNE inhibitor, discussed at ATS meeting

Tripep provides update on lead drug candidate GPG

Viozan produces rapid and sustained activation of D2 receptors and beta2-adrenoceptors

Prostanoid receptor agonist protects against warm ischemia-reperfusion injury in rat kidneys

Company Profile: Apovia

Bimosiamose blocks kidney allograft rejection and is synergistic with other agents

Sepracor seeks FDA approval to evaluate new anxiolytic in humans

Ergo Science looking to sell or license Ergoset property rights

Posttranscriptional TNF inhibitor advances towards clinical trials for IBD

Femara approved in Canada as first-line treatment for advanced breast cancer

ID Biomedical begins clinical evaluation of intranasal influenza vaccine

Curcumin may have additional potential in acute pancreatitis

Hybridon completes sale of remaining shares in MethylGene

Development and commercialization rights to ISIS-113715 licensed by Merck

Dual antiinflammatory and antiproliferative effects reported for sPLA2 inhibitor

Dynavax initiates two new phase II/III trials for ragweed allergy treatment

Company Profile: EluSys Therapeutics

First patent for oral gene delivery owned by Genteric

Atherosclerosis inhibited by anti-MCP-1 gene therapy

Peptides based on Mcep sequence and use in tuberculosis vaccines

Ergoline derivatives synthesized at Novartis useful in depression, anxiety, etc.

Orally active, nontoxic antimicrobial agents in the Aventis pipeline

Merck describes new integrin receptor antagonists and therapeutic use thereof

Kissei researchers identify potential new treatments for diabetes and related disorders

Erythromycin derivatives with potent activity against staphylococci and streptococci

New serotonergic agents from BASF covered by U.S. patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...